5 Results for "

BCR-ABLT315I

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "BCR-ABLT315I" in MCE Product Catalog:

  • Categories Recommended:
    More
Cat. No.: HY-147414
CAS No.: 1416241-23-0
Purity:  98.69%
Synonyms: PF-114
Target:  

Bcr-Abl

Research Areas:  

Cancer

Vamotinib (PF-114) is a potent, selective and orally active tyrosine kinase inhibitor. Vamotinib inhibits the autophosphorylation of BCR/ABL and BCR/ABL-T315I. Vamotinib induces apoptosis. Vamotinib shows anti-proliferative and anti-tumor activity. Vamotinib has the potential for the research of resistant philadelphia chromosome-positive (Ph+) leukemia. Vamotinib inhibits ABL series kinases with IC50s of 0.49 nM (ABL), 0.78 nM (ABL T315I), 9.5 nM (ABL E255K), 2.0 nM (ABL F317I), 7.4 nM (ABL G250E), 1.0 nM (ABL H396P), 2.8 nM (ABL M351T), 12 nM (ABL Q252H), and 4.1 nM (ABL Y253F), respectively . Vamotinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-123159
CAS No.: 1432515-73-5
Purity:  98.03%
Target:  

Aurora Kinase

Research Areas:  

Cancer

AKI603 is an inhibitor of Aurora kinase A (AurA), with an IC50 of 12.3 nM. AKI603 is developed to overcome resistance mediated by BCR-ABL-T315I mutation. AKI603 exhibits strong anti-proliferative activity in leukemic cells .
loading...
    loading...
Cat. No.: HY-10364
CAS No.: 926922-16-9
Target:  

Bcr-Abl

Research Areas:  

Cancer

AP24163 is a BCR-ABL kinase inhibitor. AP24163 inhibits wild-type (native) BCR-ABL and BCR-ABL-T315I with IC50 values of 7 nM and 511 nM, respectively. AP24163 can be used in the research of chronic myeloid leukemia (CML) .
loading...
    loading...
Cat. No.: HY-160478
CAS No.: 839708-29-1
Target:  

Bcr-Abl

Research Areas:  

Cancer

GNF-6 (Compound 14) inhibits the gatekeeper threonine residue mutation of BCR-ABL-T315I with IC50s of 0.25 μM, 0.09 μM and 0.590 μM for c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants, respectively. GNF-6, an ATP competitive inhibitor, disrupts the assembly of the hydrophobic spine (a network of hydrophobic interactions), thereby locking the kinase in an inactive ‘DFG-out’ conformation .
loading...
    loading...
Cat. No.: HY-10943R
CAS No.: 839706-07-9
Research Areas:  

Cancer

GNF-7 (Standard) is the analytical standard of GNF-7 (HY-10943). This product is intended for research and analytical applications. GNF-7 is a multiKinase inhibitor. GNF-7 is a Bcr-Abl inhibitor, with IC50s of 133 nM and 61 nM for Bcr-AblWT and Bcr-AblT315I, respectively. GNF-7 also possesses inhibitory activity against both ACK1 (activated CDC42 Kinase 1) and GCK (germinal center Kinase) with IC50s of 25 nM and 8 nM, respectively. GNF-7 can be used for the research of hematologic malignancies .
loading...
    loading...